Member Info for Wiggly

We have dropped 20% since the MSCI announcement. Today should be good!

Thoughts on this?

Did the MSCI related selling start only yesterday or did it start when the notification of Avacta dropping out was published ? Assuming it started when the notification was published and concluded in a final rush yesterday we have had some increased selling pressure for few weeks which will now be non-existent from today! There could be fireworks today if this theory is true ?

?

Fingers crossed for an RNS to set the record straight once and for all!

100% you don't bring a new site on at this very late stage IF ITS NOT ACTIVATING (cost of new site is significant ) and if it's activating then it's doing what dox does!

Why open another site for another cohort ? Surely just use same/ an existing site.

This has phase1b all over it

This suggests the safety committee have met recently and decided to introduce another site. Why is the big question?

Undeniably hugely positive !!

https://youtu.be/3ySJAbbZ0xM?t=70

In response to a question re future developments DR FM described AVA6k as 'the pathfinder'!

Have a listen and make of it what you will.

Not sure as CSO I'd be describing AVA6K as 'THE path finder ' (AND considering what else I could attach to it other than Dox/chemo) IF my asset was not doing exactly what I hoped it would be (activating in the TME)

Would she really use such a description 'THE PATH FINDER' for something that was not finding the path towards the TME?

I assume if we move to another DE Avacta will provide some additional insight as to why.

Would be fantastic if the RNS included a comment or 2 from Professor Udai, simply stating 'early days but all very excited by the data thus far' would be nice!

I haven't received an invite but that doesn't mean the CSO at Takeda also has not.

I believe the event is invite only but could be wrong?

Plenty time to update the market next week, within Nov

AS failed to deliver during the LFT DAYS with multiple missed timelines but If you look back recently it has certainly been a case of under promise and over deliver.

Take ODD as example. Didn't even mention it until an AIM sleuth posted it here !!

The science day is not for Pis. The targets (Takeda etc) may have received their invites weeks ago and Avacta may inform us next week of the date.

The fact AS seems to be as cool as a cucumber regarding Comms is positive imo. No need to ramp the share price. The data is going to do the talking here

Do we know that key targets such as Takeda, Novartis, gsk etc have not already received an invite to the science day ?

From the sky article;

Dr Olivia Rossanese, director of drug discovery at the ICR:

"Together, this three-pronged approach can create SMARTER, KINDER cancer TREATMENTS, and offer patients longer life with fewer side-effects."

From the AVA6k first Doe RNS:

AVA6000 Principal Investigator Professor Udai Banerji, Deputy Director of the Drug Development Unit at The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust commented:

“It is fantastic that efforts are being made to discover and develop SMARTER KINDER TREATMENTS.”

Nothing to see here.........

@wyn,

In response to:

'We don't know its us as all, and given AVCT tech helps attacks the Tumour, the brief news report was not highlighting this way of dealing with cancer'

Please digest and explain the following from the article;

"We want to discover better targets within tumours and the wider ecosystem that we can attack with drugs.

"We're finding powerful new ways to eradicate cancer proteins completely and discovering smarter combination treatments that attack cancer on multiple fronts.

"Together, this three-pronged approach can create smarter, kinder cancer treatments, and offer patients longer life with fewer side-effects."

Neil Bell, Chief Development Officer, Avacta Life Sciences commented:

“AVA6000 offers an exciting opportunity to improve upon the current doxorubicin treatment paradigm for patients, either as a monotherapy or in combination. We look forward to the results from our AVA6000 first-in-human clinical trial as we strive to improve the therapeutic index of doxorubicin for patients.”

AVA6000 Principal Investigator Professor Udai Banerji, Deputy Director of the Drug Development Unit at The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust commented:

“I am delighted that the first patient has now received AVA6000 in the first-in-human study. This drug harnesses our understanding of the tumour microenvironment to enhance drug delivery – targeting potent anticancer therapies to tumours and potentially sparing patients debilitating side effects. It is fantastic that efforts are being made to discover and develop smarter, kinder treatments.”

Avacta would be increasing their workforce via hiring a pre clinical director to join DR FM if preCISION was not now proven (with multiple pre clinical candidates now in play)?

I'm all ears.

The more important point is that Avacta are hiring a pre clinical director... Obviously this is the sort of appointment you would make when your lead technology fails....

..

Rah,

Why do we have such a disconnect between the reality of what is developing Vs market value ?

Great post, RAH.

It would be an absolute farce if Avacta were promoting that Billboard statement of ambition while in knowledge preCISION had not already proven the Mechanism of Action.

It would also be an absolute farce for Dr FM to present pre clinical (x2) this far into the clinical trial if the preCISION mechanism of action had not been confirmed.

It would be a farce for the Safety committee to allow the trial to run for this long, x4 cohorts, if preCISION mechanism of action had not been confirmed.

It would be extremely odd to be granted ODD if Avacta had not shared evidence of the preCISION mechanism of action working in human.

With preCISION mechanism of action proven (must be based on the above ) and Safety + tolerability improved Vs DOX (De4 confirms this) Avacta should already be valued at >1billion.